This inventor holds 1 USPTO granted patent. Top assignee: Shanghai Pharmaceuticals Holding Cd., Ltd.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: **Inventor Spotlight: Wenbo Xiao**
Introduction
Wenbo Xiao is a notable inventor based in Shanghai, China, recognized for his contributions to the field of pharmaceutical chemistry. His innovative work involves developing compounds that target specific cancer pathways, showcasing the intersection of science and impactful healthcare solutions.
Latest Patents
Wenbo Xiao holds a patent for a nitrogenous heterocyclic compound, detailing its preparation method, intermediate, composition, and applications. This patented compound exhibits high inhibitory activity against ErbB2 tyrosine kinase and demonstrates significant effectiveness against human breast cancer cells (BT-474) and gastric cancer cells (NCI-N87), which are known for high ErbB2 expression. Additionally, the compound functions as an EGFR/ErbB2 double target inhibitor, selectively modulating EGFR kinase activity and providing targeted treatment options for cancer therapy.
Career Highlights
Wenbo Xiao is currently associated with Shanghai Pharmaceuticals Holding Co., Ltd., where he contributes valuable expertise to ongoing research and development in pharmaceutical innovations. His role involves both inventive contributions and the strategic application of his findings to ensure effective medical treatments.
Collaborations
Throughout his career, Wenbo has collaborated with esteemed colleagues, including Guangxin Xia and Di Li, to advance their projects in pharmaceutical chemistry. These collaborations emphasize the importance of teamwork in achieving significant breakthroughs in drug development, combining diverse expertise to enhance overall research outcomes.
Conclusion
Wenbo Xiao is an exemplary figure in the realm of pharmaceutical innovation. His dedication to creating targeted cancer therapies through his patented compounds not only highlights his inventiveness but also reflects a broader commitment to improving healthcare solutions. As he continues to push the boundaries of pharmaceutical research, his work remains a vital asset to the field of oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile